Elevated neutrophil‐to‐lymphocyte ratio (<scp>NLR</scp>) is associated with poorer progression‐free survival in unresectable stage<scp>III NSCLC</scp>treated with consolidation durvalumab-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Elevated neutrophil‐to‐lymphocyte ratio (NLR) is associated with poorer progression‐free survival in unresectable stageIII NSCLCtreated with consolidation durvalumab

Published:2022-09-16 Issue:21 Volume:13 Page:3058-3062
ISSN:1759-7706
Container-title:Thoracic Cancer
language:en
Short-container-title:Thoracic Cancer

Author:

Nindra Udit¹^ORCID,Shahnam Adel²,Stevens Samuel³,Pal Abhijit¹,Nagrial Adnan²⁴,Lee Jenny³⁵,Yip Po Yee⁶⁷,Adam Tamiem⁸,Boyer Michael³⁴,Kao Steven³⁴,Bray Victoria¹⁸

Affiliation:

1. Department of Medical Oncology Liverpool Hospital Sydney Australia

2. Department of Medical Oncology Westmead Hospital Sydney Australia

3. Department of Medical Oncology Chris O'Brien Lifehouse Sydney Australia

4. Sydney Medical School The University of Sydney Sydney Australia

5. Department of Clinical Medicine Macquarie University Sydney Australia

6. Department of Medical Oncology Macarthur Cancer Therapy Center, Campbelltown Hospital Sydney Australia

7. School of Medicine Western Sydney University Sydney Australia

8. Department of Medical Oncology Bankstown‐Lidcombe Hospital Sydney Australia

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/1759-7714.14646

Reference18 articles.

1. Longitudinal tumor size and NLR as predictive factors of individual survival compared to their baseline values in patients with non-small cell lung cancer treated with durvalumab.

2. Inflammation and cancer

3. Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-small-cell lung carcinoma

4. Inhibition of human cytotoxic T lymphocyte activity in vitro by autologous peripheral blood granulocytes;Petrie HT;J Immunol,1985

5. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Derived neutrophil-to-lymphocyte ratio has the potential to predict safety and outcomes of durvalumab after chemoradiation in non-small cell lung cancer;Scientific Reports;2024-08-23

2. Predictive Efficacy of the Advanced Lung Cancer Inflammation Index in Hepatocellular Carcinoma After Hepatectomy;Journal of Inflammation Research;2024-08

3. Systemic and local immunosuppression in glioblastoma and its prognostic significance;Frontiers in Immunology;2024-02-28

4. Durvalumab Outcomes in Stage III Non-small Cell Lung Cancer: A Single-institution Study;Anticancer Research;2024-02

5. Neutrophil-to-Lymphocyte Ratio (NLR) in NSCLC, Gastrointestinal, and Other Solid Tumors: Immunotherapy and Beyond;Biomolecules;2023-12-18

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3